INTRODUCTION
Coronary angiography and eventual revascularization have become the most common approaches for patients with acute coronary syndromes. Although ischemia detection is usually regarded as unnecessary for most of these patients, some recent data suggested that it could have a role in the decision-making process.
ST-elevation myocardial infarction (STEMI) with multivessel disease
The best treatment for STEMI is to rapidly open the infarct-related artery (IRA), which is better achieved by angioplasty [1] . However, having done this, patients may still have significant coronary stenoses in up to 40% to 60% of the cases. These patients likely have higher atherosclerotic burden with increased risk, and it is not clear how to prevent their risk. Also, these patients may have worse left ventricular function.
In the last years several studies have dealt with the issue of multivessel disease (MVD) after STEMI treated with primary angioplasty, and these studies have been changing the guidelines ever since. Thus, guidelines in 2013 recommended exclusive treatment of the IRA [2] reserving treatment of MVD just in cases of cardiogenic shock or persistent ischemia (indication IIa-class B), whereas the last guidelines recommend routine revascularization of MVD before hospital discharge (indication IIa-class A) [3] . The PRAMI [4] and CvLPRIT [5] studies randomized patients with STEMI and MVD disease to an IRA-only strategy vs complete revascularization and reported better outcome with the complete revascularization strategy.
Further studies like the PRIMULTI [6] and the ACUTE-COMPARE [7] randomized STEMI and MVD disease patients to an IRA-only revascularization strategy vs a complete revascularization strategy based on ischemia, as detected by flow reserveguided (FFR) < 0.80. Both studies demonstrated that the functional strategy was better than the mere revascularization of the IRA.
Recently, the CROSS-AMI study, using a completely different design, randomized patients with STEMI treated with primary angioplasty and who also had MVD to a complete anatomic revascularization of the non-infarct related artery (non-IRA) lesions vs subsequent revascularization of the non-IRA lesions only if ischemia was demonstrated by stress echocardiography [8, 9] . The main findings of this study were that only 30% of the patients in the ischemia arm needed a second revascularization and that the outcome was similar in both arms. In fact, there were 22 events in the complete revascularization arm and 21 in the ischemia-guided arm [14.3% vs 13.8%; hazard ratio (HR) = 1.06, 95% confidence interval (CI): 0.58-1.92, P = not significant]. Figure 1 shows the Kaplan-Meier event-free survival curves for both arms and Video 1 to 3 are examples of two patients randomized to the stress-guided strategy. Of note, most of the stress echocardiography studies were performed using peak treadmill exercise, a very sensitive modality [10, 11] . This study therefore showed that ischemia detection has indeed a role for avoiding procedures and saving costs in this scenario.
These results are not completely surprising because revascularization based on ischemia has led to better prognosis than revascularization based on anatomy as reported in the FAME study, where ischemia was investigated by FFR [12] . The investigators found that measurement of FFR in patients with multivessel coronary artery disease who were undergoing percutaneous coronary intervention with drugeluting stents significantly reduced the rate of the composite end point of death, nonfatal myocardial infarction, and repeat revascularization. Also, Escaned et al [13] recently reported similar results, such that the use of functional assessment based on FFR/iFR led to a 25% reduction in the use of stents.
Additional studies on this subject are ongoing. For instance, the FULL-REVASC . This figure is adapted from Calviño-Santos et al [8] . HR: Hazard ratio; CI: Confidence interval. study will randomize patients with STEMI and MVD to an initial conservative management of non-IRA lesions vs FFR-guided revascularization of non-culprit lesions during hospitalization (https://www.ucr.uu.se/fullrevasc/).
However, as it is clear from above, the optimum study would be one with three arms comparing conservative management of non-IRA stenoses, complete anatomic revascularization and ischemia/FFR-guided revascularization. Meanwhile, it is worth stating that the current approach in our center for patients with STEMI and multivessel coronary artery disease is based on ischemia.
NON-ST-ELEVATION ACUTE CORONARY SYNDROME
In patients with non-ST-elevation acute coronary syndrome who do not have recurrence of chest pain, signs of heart failure or abnormalities in the initial or subsequent electrocardiography and increase in (preferably high-sensitivity) cardiac troponin level, a non-invasive stress test (preferably with imaging) for inducible ischemia is recommended before deciding on an invasive strategy. This recommendation has been clearly stated in the last guidelines on the issue [14] . Therefore, when there is troponin elevation, a coronary angiography is currently warranted. However, in the last decades there has been a lot of discussion on this matter, and several studies have focused on the comparison between an invasive and functional strategy for patients with non-STEMI or unstable angina. A Cochrane review [15] joining all studies published between 2001 and 2012 and including almost 9000 patients found that there was no significant differences in mortality [risk ratio (RR) = 0.87; CI: 0.64-1.18] or in the composite of mortality and non-fatal myocardial infarction (RR = 0.93; CI: 0.71-1.2). Less hard end-points like myocardial infarction (RR = 0.79; CI: 0.63-1), refractory angina (RR = 0.64; CI: 0.52-0.79) and rehospitalization (RR = 0.77; CI: 0.63-0.94) were lower with the invasive strategy. In contrast, complications of angiography or revascularization like bleeding or procedure-related myocardial infarction were higher in the invasive arms (RR = 1.73, CI: 1.2-2.31; and RR = 1.87, CI: 1.47-2.37). Therefore, the conclusion of this meta-analysis was that in patients with non-ST-elevation acute coronary syndrome, a conservative strategy based on clinical risk for recurrent events is the preferred management strategy. However, it is worth stating that the use of stents was lower (50% to 88% of the patients), and the use of coronary artery by-pass was higher (up to 10% to 41% of revascularizations). Also, antiplatelet therapy was less developed. On the other hand, functional testing consisted of just exercise electrocardiography for most of the patients.
In this regard, the only old study that clearly observed a superiority of a functional approach in patients with non-STEMI was the VANQUISH trial [16] . Unlike other conceptually similar studies, the conservative strategy of the VANQUISH was in fact a "conservative aggressive strategy" as almost half of the patients in this arm underwent coronary angiography. Another key point was that almost all patients in the conservative arm were studied by treadmill exercise with myocardial perfusion imaging, which is a very sensitive technique, or by dypiridamole myocardial perfusion imaging in case of the inability to exercise. Although the VANQUISH trial was a pre-stent study, these aspects may explain the superiority of the conservative strategy over the invasive strategy regarding both the primary end-point (P = 0.007) and all-cause death (P = 0.004).
Some of these studies comparing invasive and conservative approaches have long term follow-up. Fox et al [17] published the joint results of the fast revascularization during instability in coronary artery disease (FRISC-II), randomized intervention trial of unstable angina 3 (RITA-3) and invasive vs conservative treatment in unstable coronary syndromes (ICTUS) at 5 years, demonstrating superiority of an invasive strategy for the combination of cardiovascular death and myocardial infarction (HR = 0.8, CI: 0.71-0.93, P = 0.002), which was driven for myocardial infarction occurrence (HR = 0.77; CI: 0.65-0.90, P = 0.001); the difference in cardiovascular mortality did not reach statistical significance (HR = 0.83, CI: 0.68-1.01, P = 0.068). However, these differences were at expense of the results of the FRISC-II and RITA-3 studies, as in the ICTUS study there were no significant differences between arms.
We were curious what the differences between the ICTUS study and the other studies were. Crucial differences were that the percentage of angiographies in the conservative arm of ICTUS reached up to 53% of the patients, and all patients in the conservative arm were studied by a sensitive imaging technique (both characteristics similar to the older VANQUISH study). Table 1 depicts these differences between studies. In fact, the ICTUS trial at 10 years demonstrated an excess of the combined event (death or myocardial infarction) in the invasive arm as compared to the conservative arm (HR = 1.30, CI: 1.07-1.58, P = 0.009) [18] . In addition, both the RITA-3 at 10 years and the FRISC-II at 15 years, which were studies that had shown better performance of an invasive strategy in the first years, found no significant differences in mortality between arms at longer-term follow-up [19, 20] . Therefore, given these results, it is not surprising that some experts have advocated for a fair study comparing the two strategies in a current era of imaging of high quality and sensitivity, last generation stents, radial access and modern antithrombotic therapy [21] . The use of exercise electrocardiography testing in most of the conservative arms of the above-mentioned studies (if performed) should be considered as an important limitation. The superiority of modern techniques of imaging like stress echocardiography [10, 11] , magnetic resonance or myocardial perfusion imaging would likely make a difference for stratification of these patients.
CONCLUSION
In patients with acute myocardial infarction and MVD, ischemia detection may be useful for clinical decisions. In non-ST elevation myocardial infarction or acute coronary syndrome, the ultimate role of ischemia detection for clinical decision making process in the current era of modern imaging and new drugs and stents is pending. 
